association
Full identifier: http://purl.org/np/RAKlmmJGIj7rlkDz5QVq2ufF1DmyEDfkLewGyLb8DCC5E#association
Assigned to 1 class:
Minted in Nanopublication
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAKlmmJGIj...#association
This association
http://www.w3.org/2000/01/rdf-schema#label
has label
(this is a literal)
""Benzphetamine hydrochloride tablets are contraindicated in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to sympathomimetic amines, and glaucoma. Benzphetamine should not be given to patients who are in an agitated state or who have a history of drug abuse. Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. Benzphetamine hydrochloride should not be used concomitantly with other CNS stimulants. Benzphetamine hydrochloride may cause fetal harm when administered to a pregnant woman. Amphetamines have been shown to be teratogenic and embryotoxic in mammals at high multiples of the human dose. Benzphetamine hydrochloride is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Insulin requirements in diabetes mellitus may be altered in association with use of anorexigenic drugs and the concomitant dietary restrictions. Psychological disturbances have been reported in patients who receive an anorectic agent together with a restrictive dietary regime. Caution is to be exercised in prescribing amphetamines for patients with even mild hypertension. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly. Efficacy of benzphetamine hydrochloride tablets in combination with other anorectic agents has not been studied and the combined use may have the potential for serious cardiac problems. Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. Benzphetamine hydrochloride should not be used concomitantly with other CNS stimulants. Amphetamines may decrease the hypotensive effect of antihypertensives. Amphetamines may enhance the effects of tricyclic antidepressants. Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines. Urinary acidifying agents decrease blood levels and increase excretion of amphetamines. Animal studies to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility have not been performed. Pregnancy Category X (see CONTRAINDICATIONS Section). Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing. Safety and effectiveness in pediatric patients have not been established. Use of benzphetamine hydrochloride is not recommended in individuals under 12 years of age. Clinical studies of benzphetamine hydrochloride tablets did not include sufficient numbers of subjects aged 65 and over to establish safety and efficacy in this population. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.""
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAKlmmJGIj...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
has drug
https://identifiers.org/drugbank:DB00865
drugbank:DB00865
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAKlmmJGIj...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
has disease
http://purl.obolibrary.org/obo/DOID_2349
DOID_2349
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAKlmmJGIj...#association
This association
https://w3id.org/biolink/vocab/relation
has relation
https://schema.org/MedicalContraindication
A condition or factor that serves as a reason to withhold a certain medical therapy.
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAKlmmJGIj...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
has type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
association Statement
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAKlmmJGIj...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
has predicate
https://w3id.org/biolink/vocab/treats
treats
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAKlmmJGIj...#association
This association
https://w3id.org/biolink/vocab/provided_by
is provided by
https://w3id.org/um/NeuroDKG
NeuroDKG
.
This is the identifier for the assertion of this nanopublication.
http://purl.org/np/RAKlmmJGIj...#assertion
The assertion above
http://www.w3.org/ns/prov#wasAttributedTo
is attributed to
https://orcid.org/0000-0002-1468-3557
me (Leoni Bücken)
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAKlmmJGIj...
This nanopublication
http://purl.org/dc/terms/creator
is created by
https://orcid.org/0000-0002-1468-3557
me (Leoni Bücken)
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAKlmmJGIj...
This nanopublication
date and time when the nanopublication was created
http://purl.org/dc/terms/created
was created on
(this is a literal)
"2021-08-23T12:18:22.610+02:00"
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAKlmmJGIj...
This nanopublication
links to the assertion template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
was created from the assertion template
http://purl.org/np/RAhNHZw6Ur...
RAhNHZw6Ur
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAKlmmJGIj...
This nanopublication
links to the provenance template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
was created from the provenance template
http://purl.org/np/RANwQa4ICW...
RANwQa4ICW
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAKlmmJGIj...
This nanopublication
links to the publication info template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
was created from the publication info template
http://purl.org/np/RAA2MfqdBC...
RAA2MfqdBC
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAKlmmJGIj...#sig
sig
http://purl.org/nanopub/x/hasSignatureTarget
has as target
This is the identifier for this whole nanopublication.
http://purl.org/np/RAKlmmJGIj...
this nanopublication
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAKlmmJGIj...#sig
sig
http://purl.org/nanopub/x/hasAlgorithm
has the algorithm
(this is a literal)
"RSA"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAKlmmJGIj...#sig
sig
http://purl.org/nanopub/x/hasPublicKey
has the public key
(this is a literal)
"MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAKlmmJGIj...#sig
sig
http://purl.org/nanopub/x/hasSignature
has the signature
(this is a literal)
"ToNryLfuel2iLVZUq1R9BNi5qWrqRIgo0QlIQNPalvLNfZgHpm3d7mLHiGEhbcW0koAeKz84WYIPzimYHBZPbUz4QEBRWyGVd+AnVnCPF9xYCPY4VZqyxxgTN35D2t8vLg+GvgshZNulmOVkYhWzrqWx5ELVPYPBFK9ZxzhtEkY="
.
References
Nanopublication | Part | Subject | Predicate | Object | Published By | Published On |
---|---|---|---|---|---|---|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-08-23T10:18:22.610Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
"Benzphetamine hydrochloride tablets are contraindicated in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to sympathomimetic amines, and glaucoma. Benzphetamine should not be given to patients who are in an agitated state or who have a history of drug abuse. Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. Benzphetamine hydrochloride should not be used concomitantly with other CNS stimulants. Benzphetamine hydrochloride may cause fetal harm when administered to a pregnant woman. Amphetamines have been shown to be teratogenic and embryotoxic in mammals at high multiples of the human dose. Benzphetamine hydrochloride is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Insulin requirements in diabetes mellitus may be altered in association with use of anorexigenic drugs and the concomitant dietary restrictions. Psychological disturbances have been reported in patients who receive an anorectic agent together with a restrictive dietary regime. Caution is to be exercised in prescribing amphetamines for patients with even mild hypertension. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly. Efficacy of benzphetamine hydrochloride tablets in combination with other anorectic agents has not been studied and the combined use may have the potential for serious cardiac problems. Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. Benzphetamine hydrochloride should not be used concomitantly with other CNS stimulants. Amphetamines may decrease the hypotensive effect of antihypertensives. Amphetamines may enhance the effects of tricyclic antidepressants. Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines. Urinary acidifying agents decrease blood levels and increase excretion of amphetamines. Animal studies to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility have not been performed. Pregnancy Category X (see CONTRAINDICATIONS Section). Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing. Safety and effectiveness in pediatric patients have not been established. Use of benzphetamine hydrochloride is not recommended in individuals under 12 years of age. Clinical studies of benzphetamine hydrochloride tablets did not include sufficient numbers of subjects aged 65 and over to establish safety and efficacy in this population. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."
|
Leoni Bücken
|
2021-08-23T10:18:22.610Z
|
||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-08-23T10:18:22.610Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-08-23T10:18:22.610Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-08-23T10:18:22.610Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-08-23T10:18:22.610Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-08-23T10:18:22.610Z
|